Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04021316
Other study ID # 19CX5371
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date October 1, 2019
Est. completion date April 10, 2023

Study information

Verified date September 2023
Source Imperial College London
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Does the use of decellularised dermis allograft in addition to compression therapy promote healing in chronic venous leg ulceration compared to compression therapy alone


Description:

Chronic venous ulceration are open wounds on the lower limbs which have been present for at least three months and are caused by a poorly functioning venous system. The affect about 1% of the general population and about 4% of those over 65. The wounds cause pain, reduced movement, and can smell - greatly affecting the quality of life of leg ulcer patients. The standard care for these patients is compression bandaging, which requires changing several times a week by community or district nurses; this drives the high cost of leg ulcer care, which can amount to £2.5 billion per annum. Skin grafting can be used alongside compression bandaging and can help the ulcers heal faster than compression alone. Grafts can be taken from the patient's own skin, from a donor or from tissue engineered skin. An autograft (using own skin) can cause scarring and the need for a formal surgical procedure in theatre so are not suitable for all ulcer patients. Allografts (donor skin) and xenografts (animal skin) have been used successfully, but present similar drawbacks to autografts, plus the potential for the body to reject the graft and disease transmission. Tissue engineered skin has several advantages as it has been processed to remove the cells, and therefore is won't be rejected via the immune response. Human decellularised dermis (DCD) is generated from donated skin from deceased people and processed to remove the cells. It can be glued or sewn onto the skin under local anesthetic, in an out patient setting. DCD has mainly been studied in patients with diabetic foot ulceration and has shown improved healing rates and quality of life. This study will investigate the use of DCD in addition to compression therapy versus compression therapy alone in patients with chronic venous leg ulceration.


Recruitment information / eligibility

Status Terminated
Enrollment 71
Est. completion date April 10, 2023
Est. primary completion date April 10, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - =18 years or older (no upper age limit) - The ability to consent to participation - A diagnosis of venous leg ulceration* (defined as 'colour duplex confirmation of superficial and or deep venous reflux with any break in the skin that has either: a) been present for more than 2 weeks, or b) occurred in a person with a history of venous leg ulceration) - Documented venous incompetence on duplex ultrasound - Index ulcer wound duration of greater than 3 months - Index ulcer wound size = 2 cm2. - ABPI = 0.8 - in light of the Covd-19 pandemic, the use of handheld continuous wave Dopplers will be allowed to diagnose venous disease to allow participants to be recruited from clinic without the need for an imaging appointment Exclusion Criteria: - A diagnosis of sickle cell - Unable to receive one or more of the randomised treatment strategies for any reason at the discretion of the attending clinical team (e.g. known allergies to dCELL dermis preparation components) - A clinically infected ulcer defined as evidence of erythema, cellulitis or systemically unwell - Treatment with biomedical/topical growth factors within previous 30 days - Previous history of an inability to tolerate compression therapy - Foot ulcer (i.e. below the ankle)

Study Design


Related Conditions & MeSH terms


Intervention

Other:
dCELL® Human Dermis (decellularised dermal skin allograft - DCD)
DCD is produced from split thickness skin grafts (which comprise the epidermis and upper part of the dermis), and is retrieved from deceased tissue donors. All epidermal and cellular components from the dermis are removed in a patented sequential decellularisation process. As a decellularised graft, dCELL® Human Dermis fully integrates into the wound bed after application, replacing lost dermal tissue. It provides a scaffold into which the recipient's cells can grow, becoming vascularised and supporting the generation of a new epidermis, ultimately regenerating into normal skin.
Compression bandaging therapy
Compression therapy will be according to local practice and may include multilayer elastic compression bandaging or stockings delivering 20 to 40mm/Hg pressure.

Locations

Country Name City State
United Kingdom North Bristol NHS Trust Bristol
United Kingdom Cardiff and Vale University Health Board Cardiff
United Kingdom North Cumbria University Hospitals NHS Trust Carlisle
United Kingdom Gloucestershire Hospitals NHS Foundation Trust Gloucester
United Kingdom AT Medics London
United Kingdom Guy's and St Thomas' NHS Foundation Trust London
United Kingdom Imperial College Healthcare NHS Trust London
United Kingdom London North West University Healthcare London
United Kingdom St Charles Centre for Health and Welbeing, Central London Community Healthcare NHS Trust London
United Kingdom Aneurin Bevan University Health Board Newport
United Kingdom Northampton General Hospital NHS Trust Northampton
United Kingdom Livewell Plymouth
United Kingdom University Hospitals Plymouth NHS Trust Plymouth
United Kingdom Swansea Bay University Health Board Swansea
United Kingdom Taunton and Somerset NHS Foundation Trust Taunton
United Kingdom Mid Yorkshire Hospitals NHS Trust Wakefield
United Kingdom Worcestershire Acute Hospitals NHS Trust Worcester

Sponsors (8)

Lead Sponsor Collaborator
Imperial College London Cambridge University Hospitals NHS Foundation Trust, Gloucestershire Hospitals NHS Foundation Trust, NHS Blood and Transplant, Universidad de Granada, University of Birmingham, University of Edinburgh, University of Manchester

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion with a healed index ulcer at 12 weeks after randomisation. 12 weeks
Secondary Time to index ulcer healing from randomisation 12 months
Secondary The percentage change in index ulcer area in cm2 at 12 weeks from randomisation 12 weeks
Secondary The proportion of participants with a healed index ulcer at 12 months from randomisation 12 months
Secondary The proportion of participants whose index ulcer healed for whom an ulcer recurred at the index site within 12 months from randomisation 12 months
Secondary Generic quality of life using the EuroQol-5D (EQ-5D) questionnaire A health index on a score of 0 to 1 and the participants' self-rated health on a vertical score of zero to 100. Higher scores indicate better quality of life 12 weeks, 6 months and 12 months from randomisation
Secondary Disease specific quality of life using the Charing Cross Venous Ulcer Questionnaire (CCVUQ) Scale 0 to 100, with lower scores indicating better quality of life 12 weeks, 6 months and 12 months from randomisation
Secondary The cost for each patient, calculated from the healthcare resources used 12 months
Secondary Incremental cost-effectiveness ratio (ICER) from the EQ-5D questionnaire, with appropriate sensitivity analysis An intervention may be considered cost-effective when its ICER is less than the threshold set by health policy decision-makers. In the UK, the cost-effectiveness threshold is currently in the range £20 000-30 000 per QALY 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT05633277 - Outcomes of Sclerotherapy of the Ulcer Bed Compared to a Combination of Ablation and Injections N/A
Recruiting NCT02838784 - Efficacy and Safety of Artacent™ for Treatment Resistant Lower Extremity Venous and Diabetic Ulcers N/A
Completed NCT02092870 - Adipose Derived Regenerative Cellular Therapy of Chronic Wounds Phase 2
Terminated NCT00847002 - Flexitouch Treatment for Venous Ulcers N/A
Completed NCT01858272 - Preliminary Testing of New Treatment for Chronic Leg Wounds Phase 1
Not yet recruiting NCT05877378 - Efficacy of PICO Single-use System in Chronic Ulcers N/A
Recruiting NCT05409976 - The GORE® VIAFORT Vascular Stent IVC Study N/A
Terminated NCT01396304 - Restore Calcium Alginate Dressing, Silver vs Aquacel Ag in the Treatment of Critically Colonized Venous Leg Ulcers Phase 4
Not yet recruiting NCT06007703 - Evaluation of the Efficacy of Multilayer Compression & UrgoStart Plus
Completed NCT04046120 - Comparison of the Effectiveness of Two Medical Compression Bandage Application Techniques by Measuring Interface Pressures Depending on Whether or Not the Heel is Included in Patients With Open Venous Ulcers N/A
Completed NCT05729334 - Clinical Investigation EUCLIDES-01 for the Calculation of the Area of Skin Lesions N/A
Completed NCT03070938 - PuraPly™ Antimicrobial Wound Matrix and Wound Management N/A
Terminated NCT01853384 - Safety and Efficacy Trial of HP802-247 in the Treatment of Chronic Venous Leg Ulcers Phase 3
Completed NCT00558662 - Randomized Clinical Trial (RCT) to Compare the Efficacy of Coban 2 Versus SSB in the Treatment of Venous Leg Ulcers N/A
Completed NCT01750749 - Cell Therapy for Venous Leg Ulcers Pilot Study Phase 1
Completed NCT01327937 - A Post Marketing Study of Apligraf in Non-healing Wounds of Subjects With Venous Leg Ulcers Phase 4
Completed NCT00820196 - A Trial to Assess the Safety and Activity of Nexagon® for the Treatment of Venous Leg Ulcers (The NOVEL Study) Phase 2
Completed NCT00301496 - Randomized Controlled 8-Week Crossover Evaluation of Compression Bandage Systems for Venous Leg Ulcers N/A
Recruiting NCT05489588 - The GORE® VIAFORT Vascular Stent Iliofemoral Study N/A
Not yet recruiting NCT02798445 - TAPIRS Technique Plus Adjustable Compression System in Treatment of Venous Leg Ulcers N/A